Drugs that contain Eszopiclone
1. Lunesta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7381724 (Pediatric) | WOODWARD | Optically active 5H-pyrrolo[3,4-b]pyrazine derivative, its preparation and pharmaceutical compositions containing same |
Jul, 2012
(11 years ago) | |
|
US6319926 (Pediatric) | WOODWARD | Optically active 5H-pyrrolo[3, 4-B]pyrazine derivative, its preparation and pharmaceutical compositions containing it |
Jul, 2012
(11 years ago) | |
| US6864257 | WOODWARD | Optically active 5H-pyrrolo[3,4-b]pyrazine derivative, its preparation and pharmaceutical compositions containing it |
Aug, 2012
(11 years ago) | |
|
US6864257 (Pediatric) | WOODWARD | Optically active 5H-pyrrolo[3,4-b]pyrazine derivative, its preparation and pharmaceutical compositions containing it |
Mar, 2013
(11 years ago) | |
| US6444673 | WOODWARD | Optically active 5H-pyrrolo[3,4-b]pyrazine derivative, its preparation and pharmaceutical compositions containing it |
Feb, 2014
(10 years ago) | |
|
US6444673 (Pediatric) | WOODWARD | Optically active 5H-pyrrolo[3,4-b]pyrazine derivative, its preparation and pharmaceutical compositions containing it |
Aug, 2014
(9 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Apr 10, 2016 |
| M(M-61) | Oct 10, 2015 |
Market Authorisation Date: 15 December, 2004
Treatment: Method of inducing a hypnotic or sedative effect in a human by administering eszopiclone
Dosage: TABLET;ORAL
How can I launch a generic of LUNESTA before it's drug patent expiration?
More Information on Dosage
LUNESTA family patents
